Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Rigel Pharmaceuticals
NCT05797610 · Primary IgA Nephropathy
NCT07305116 · Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), and more
NCT07014826 · Primary IgA Nephropathy
NCT05234463 · IgA Nephropathy Severity in Kidney Transplantation
NCT06740526 · IgA Nephropathy
Stanford University Medical
Palo Alto, California
Nephrology Associates PC, University Hospital, Professional Center 1
Augusta, Georgia
Ohio State University
Columbus, Ohio
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions